Patrick Born
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patrick Born has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- David Fandrei
Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
21 shared publications - Vladan Vucinic
Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
21 shared publications - Maximilian Merz
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
20 shared publications - Nico Gagelmann
Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 shared publications - Georg-Nikolaus Franke
Department for Hematology, Cell Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany
13 shared publications - Enrica Bach
Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
12 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Covariate balance before and after IPTW
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Covariate balance before and after IPTW
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
IPTW-weighted Kaplan-Meier estimates at 12 months
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
IPTW-weighted Kaplan-Meier estimates at 12 months
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Patient flow and applied analyses. Top panel – entire cohort. Middle panel – cohort for the primary multistate models and landmark analyses. Lower panel – IPTW analysis.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Patient flow and applied analyses. Top panel – entire cohort. Middle panel – cohort for the primary multistate models and landmark analyses. Lower panel – IPTW analysis.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Observed survival according to first immunotherapy
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Observed survival according to first immunotherapy
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
RPSFTM-adjusted overall survival by initial treatment modality. RPSFTM-adjusted overall survival. The observed CAR T-first curve (solid dark blue) is compared with the observed BsAb-first curve (dashed crimson) and the RPSFTM-adjusted BsAb-first curve (solid orange). The adjusted curve represents the counterfactual survival of BsAb-first patients had no treatment switching to CAR T occurred, estimated using rank-preserving structural failure time modeling with g-estimation. Number at risk tables are shown below each panel. All estimates are descriptive and should be interpreted in the context of non-randomized treatment allocation and the assumptions of the RPSFTM framework.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
RPSFTM-adjusted overall survival by initial treatment modality. RPSFTM-adjusted overall survival. The observed CAR T-first curve (solid dark blue) is compared with the observed BsAb-first curve (dashed crimson) and the RPSFTM-adjusted BsAb-first curve (solid orange). The adjusted curve represents the counterfactual survival of BsAb-first patients had no treatment switching to CAR T occurred, estimated using rank-preserving structural failure time modeling with g-estimation. Number at risk tables are shown below each panel. All estimates are descriptive and should be interpreted in the context of non-randomized treatment allocation and the assumptions of the RPSFTM framework.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Sensitivity analysis for 6-month landmark.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Sensitivity analysis for 6-month landmark.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
IPTW-adjusted hazard ratios (univariable)
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
IPTW-adjusted hazard ratios (univariable)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Overview of bridging therapies and clinical characteristics.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Overview of bridging therapies and clinical characteristics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Detailed overview of all regimens administered as bridging therapy for each patient.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Detailed overview of all regimens administered as bridging therapy for each patient.